December 5, 2018 / 9:47 PM / 11 days ago

AbbVie halts late-stage trial for lung cancer drug Rova-T

Dec 5 (Reuters) - AbbVie said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

The committee’s recommendations were based on shorter overall survival in the Rova-T arm, compared with the topotecan control arm, the company said. (Reporting by Soundarya J in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below